The original success of Sildenafil undeniably reshaped the drug landscape, but investing in companies heavily reliant on generic versions presents a challenging picture. Although early profits were impressive, the expiration of patents and the rise of discounted alternatives have weakened sales. Thus, a thorough analysis of current revenue streams